OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
CHICAGO, May 24, 2017 -- Allscripts shareholders elected Mara G. Aspinall to serve as director. Aspinall is president and CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. Aspinall is also executive chairman of GenePeeks, a computational genomics company, and is a member of the Board of Directors of Abcam plc (AIM:ABC), Castle Biosciences and Blue Cross Blue Shield Arizona. All of Allscripts other current directors were also reelected.
“Mara has deep industry knowledge and we’re honored to welcome her to the Board of Directors,” said Allscripts CEO Paul M. Black. “Her passion for innovation and keen insights will strengthen our ability to lead the change in health care.”
Prior to joining Health Catalysts, Aspinall was president and CEO of Ventana Medical Systems division of Roche, a worldwide leader in development and commercialization of tissue-based cancer diagnostics. She previously spent 12 years as president of Genzyme Genetics and Genzyme Pharmaceuticals.
In addition to running commercial enterprises, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University, the first school dedicated entirely to Diagnostics as an independent discipline.
Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2017 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact: Investors: Seth Frank 312-506-1213 [email protected] Media: Tom Lynch 312-386-6765 [email protected]
